Could a heart drug boost colon cancer treatment?
NCT ID NCT07549906
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests if adding a common heart medication (propranolol) to standard chemotherapy and immunotherapy before surgery can improve outcomes for people with a certain type of colon cancer. About 45 adults with stage II or III colon cancer that is mismatch repair proficient (pMMR) will receive either the standard combination or the standard plus propranolol. The main goal is to see how much the tumor shrinks before surgery.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BETA-BLOCKER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Your gut bacteria might hold the key to lung cancer treatment
- Can an AI coach and simple exercises help cancer patients fight frailty?
- Triple therapy takes on rare, aggressive kidney cancer
- Bladder cancer drug delivered directly: a new hope for BCG failures
- Immunotherapy combo may boost rectal cancer treatment
- New cocktail aims to make immunotherapy work for common colorectal cancer